PharmaCyte Biotech (NASDAQ:PMCB) Releases Quarterly Earnings Results

PharmaCyte Biotech (NASDAQ:PMCB) posted its quarterly earnings results on Monday. The company reported ($0.10) EPS for the quarter, Zacks reports.

PharmaCyte Biotech Stock Down 5.1 %

Shares of NASDAQ:PMCB opened at $1.50 on Wednesday. The company has a market cap of $10.30 million, a PE ratio of 2.83 and a beta of -0.25. The company’s 50-day moving average price is $1.64 and its 200 day moving average price is $1.70. PharmaCyte Biotech has a fifty-two week low of $1.39 and a fifty-two week high of $2.58.

About PharmaCyte Biotech

PharmaCyte Biotech, Inc, a biotechnology company, develops and commercializes cellular therapies for cancer in the United States. Its cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer, including advanced and inoperable pancreatic cancer.